Unitys eye treatment fails to match Eylea, though analysts still see a path forward
Unity Biotechnology's investigational eye treatment UBX1325 failed to match Eylea (aflibercept) in a phase 2b study for diabetic macular edema (DME), though some analysts still see potential paths forward for the drug7.
Key points:
-
The study missed its primary endpoint of non-inferiority to Eylea in improving visual acuity at 20-24 weeks7.
-
UBX1325 showed a 3.7 letter gain from baseline vs 5.1 for Eylea at the 20-24 week average7.
- However, UBX1325 matched or outperformed Eylea at other timepoints:
* - At 24 weeks:*
5.2 letter gain for UBX1325 vs 4.8 for Eylea7
* - At 36 weeks:*
5.5 letter gain for UBX1325 (in 75% of patients with data so far)7
-
UBX1325 was superior to Eylea at 7 out of 10 timepoints in patients with moderately aggressive disease (about 60% of patients)7.
-
The drug demonstrated a favorable safety and tolerability profile7.
Despite the primary endpoint miss, analysts from Mizuho still see potential paths forward, particularly in the moderately aggressive disease subgroup7. Unity's CEO expressed excitement about the vision improvements seen in difficult-to-treat patients7.
Unity plans to advance UBX1325 to late-stage studies against Eylea in DME patients with inadequate response to anti-VEGF therapies7. The company's stock fell 33% following the news7.
Sources:
7. https://www.fiercebiotech.com/biotech/unitys-eye-treatment-fails-match-eylea-though-analysts-still-see-path-forward